Intelligence / Healthtech / New Clinical Trials / Interlude Biopharma Co.
Clinicaltrial registered18 Nov 2026
Interlude Biopharma Co.
18 Nov 2026: Trial registered · Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac Disease. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 18 Nov 2026
- Title
- Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac Disease
- Conditions
- Celiac Disease, Celiac Disease in Adolescents
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07944625
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Interlude Biopharma Co.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.